Drug Sponsors

Baxalta opens Global Innovation Center

Friday, December 4, 2015

Baxalta, a global biopharmaceutical provider dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, has announced the official opening of its Global Innovation Center in Cambridge, Mass.

[Read More]

Human Longevity acquires Cypher Genomics

Monday, November 30, 2015

San Diego’s Human Longevity Inc. (HLI), a genomics-based, technology-driven company, has acquired Cypher Genomics, a genome informatics company offering human genomic interpretation software solutions. The company has 14 employees who will join HLI, including Cypher CEO and co-founder Ashley Van Zeeland, Ph.D., who now is the head of HLI’s pediatric business. Financial details of the deal were not disclosed.

[Read More]

Pfizer, Allergan to merge in $160B transaction

Monday, November 23, 2015

Pfizer and Allergan have entered into a definitive merger agreement in a stock transaction currently valued at $363.63 per Allergan share, for a total enterprise value of about $160 billion, based on the closing price of Pfizer common stock of $32.18 on Nov. 20. The transaction represents more than a 30% premium based on Pfizer’s and Allergan’s unaffected share prices as of Oct. 28. Allergan shareholders will receive 11.3 shares of the combined company for each of their Allergan shares, and Pfizer stockholders will receive one share of the combined company for each of their Pfizer shares.

[Read More]

Mylan acquires Famy Care businesses

Monday, November 23, 2015

Mylan Laboratories, a subsidiary of Mylan, has successfully completed the acquisition of certain women’s healthcare businesses, now known as Jai Pharma, which were spun off from Famy Care. The transaction brings Mylan a broad women’s care portfolio, strong technical capabilities and dedicated hormone manufacturing, which, when combined with Mylan’s expansive global commercial footprint and supply chain infrastructure, will create a leading women’s healthcare franchise.

[Read More]

Horizon withdraws offer to acquire Depomed

Monday, November 23, 2015

Horizon Pharma, a Dublin-based biopharmaceutical company, has announced that at a hearing, Judge Peter Kirwan of the Superior Court of California for the County of Santa Clara granted Depomed‘s motion for preliminary injunctive relief against Horizon Pharma’s alleged use of information that Depomed claimed was confidential. In his ruling, Judge Kirwan did not grant the injunctive relief Horizon Pharma had sought regarding the legality of Depomed’s poison pill and certain of the bylaw amendments announced by Depomed’s board of directors on July 13.

[Read More]

Merck to expand in Africa

Monday, November 23, 2015

Merck, based in Germany, plans to considerably expand its presence on the African continent over the next five years and is counting on the region’s entrepreneurial spirit and innovation power for growth.

[Read More]